The CADILLAC risk score accurately identifies patients at low risk for in-hospital mortality and adverse cardiovascular events following ST elevation myocardial infarction

被引:4
|
作者
Wilson, Ryan S. [1 ]
Malamas, Peter [1 ]
Dembo, Brent [1 ]
Lall, Sumeet K. [1 ]
Zaman, Ninad [1 ]
Peterson, Brandon R. [1 ]
机构
[1] Penn State Coll Med, Penn State Milton S Hershey Med Ctr, Dept Med, 500 Univ Dr,Box H047, Hershey, PA 17033 USA
关键词
ST segment elevation myocardial infarction; Coronary artery disease; Risk stratification; PERCUTANEOUS CORONARY INTERVENTION; EARLY DISCHARGE; PRIMARY ANGIOPLASTY; COST-EFFECTIVENESS; SEGMENT ELEVATION; PRIMARY PCI; SAFETY; FEASIBILITY; LENGTH; TRIAL;
D O I
10.1186/s12872-021-02348-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The CADILLAC risk score was developed to identify patients at low risk for adverse cardiovascular events following ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PPCI). Methods We performed a single center retrospective review of STEMI hospitalizations treated with PPCI from 2014 to 2018. Patients were stratified using the CADILLAC risk score into low risk, intermediate risk and high risk groups. Patients presenting with cardiac arrest or cardiogenic shock were excluded from the study. The primary outcome was adverse clinical events during initial hospitalization. Secondary outcomes were adverse clinical events at 30 days and 1 year following index hospitalization. Results The study included 341 patients. Compared to patients with a low CADILLAC score, adverse clinical events were similar in the intermediate risk group during hospitalization (OR 1.23, CI 0.37-4.05, p 0.733) and at 30 days (OR 2.27, CI 0.93-5.56, p 0.0733) while adverse clinical events were significantly elevated in the high risk group during hospitalization (OR 4.75, CI 1.91-11.84, p 0.0008) and at 30 days (OR 8.73, CI 4.02-18.96, p < 0.0001). At 1 year follow-up, compared to the low risk CADILLAC group (9.4% adverse clinical event rate), cumulative adverse clinical events were significantly higher in the intermediate risk group (22.9% event rate, OR 2.86, CI 1.39-5.89, p 0.0044) and in the elevated risk group (58.6% event rate, OR 13.67, CI 6.81-27.43, p < 0.0001). The mortality rate was 0% for patients defined at low risk by CADILLAC score during hospitalization, as well up to 1 year follow up. On receiver operating curve analysis, discrimination of in-hospital adverse clinical events was fair using CADILLAC (C = 0.66, odds ratio 1.18; 95% CI 1.04-1.33; p = 0.0064) with somewhat better discrimination at 30-day follow-up (C = 0.719) and 1-year follow-up (C = 0.715). Conclusion Patients defined as low risk by the CADILLAC score following a STEMI were associated with lower mortality and adverse clinical event rates during hospitalization and up to 1 year following STEMI when compared to those with an intermediate or high CADILLAC score.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Predictors of in-hospital mortality in diabetic patients with non-ST-elevation myocardial infarction
    Seyyed Mojtaba Ghorashi
    Mojtaba Salarifar
    Hamidreza Poorhosseini
    Saead Sadeghian
    Arash Jalali
    Hassan Aghajani
    Ali-Mohammad Haji-Zeinali
    Negar Omidi
    The Egyptian Heart Journal, 74
  • [42] Predictors of in-hospital mortality in diabetic patients with non-ST-elevation myocardial infarction
    Ghorashi, Seyyed Mojtaba
    Salarifar, Mojtaba
    Poorhosseini, Hamidreza
    Sadeghian, Saead
    Jalali, Arash
    Aghajani, Hassan
    Haji-Zeinali, Ali-Mohammad
    Omidi, Negar
    EGYPTIAN HEART JOURNAL, 2022, 74 (01):
  • [43] In-hospital Mortality with Relation to Time of Presentation in Patients with Acute ST Elevation Myocardial Infarction
    Sattar, Abdul
    Bari, Abdul
    Naqvi, Moazam Ali
    Noeman, Ahmad
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2014, 8 (01): : 99 - 104
  • [44] Prediction of mortality following primary percutaneous coronary intervention for acute myocardial infarction: The CADILLAC risk score
    Nikolsky, E
    Singh, M
    Grines, CL
    Tcheng, JE
    Garcia, E
    Cox, DA
    Turco, M
    Stuckey, TD
    Na, Y
    Lansky, AJ
    Gersh, BJ
    O'Neil, WW
    Mehran, R
    Stone, GW
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 347A - 347A
  • [45] Elevated serum osteoprotegerin levels predict in-hospital major adverse cardiac events in patients with ST elevation myocardial infarction
    Canga, Aytun
    Durakoglugil, Murtaza Emre
    Erdogan, Turan
    Kirbas, Aynur
    Yilmaz, Adnan
    Cicek, Yuksel
    Ergul, Elif
    Cetin, Mustafa
    Kocaman, Sinan Altan
    JOURNAL OF CARDIOLOGY, 2012, 60 (5-6) : 355 - 360
  • [46] Validation of clinical scoring system for predicting in-hospital mortality in non ST-segment elevation myocardial infarction; Comparison with the GRACE risk score
    Komiyama, K.
    Tanabe, K.
    Fujimoto, H.
    Oikawa, K.
    Daida, H.
    Nakamura, M.
    Yamamoto, T.
    Nagao, K.
    Takayama, M.
    EUROPEAN HEART JOURNAL, 2017, 38 : 595 - 595
  • [47] In-hospital outcome according to the initial management and thrombolysis in myocardial infarction risk score in acute Non-ST-Segment elevation myocardial infarction
    Chung, H. C.
    Jeong, M. H.
    Ahn, Y. K.
    Chae, S. C.
    Kim, J. H.
    Seong, I. H.
    Hur, S. H.
    Kim, Y. J.
    Choi, D. H.
    Hong, T. J.
    Yoon, J. H.
    Seung, K. B.
    Park, S. J.
    AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (8B): : 27C - 27C
  • [48] Red cell distribution width and KAMIR score predict in-hospital mortality of patients with ST segment elevation myocardial infarction
    蔡美鹏
    凌云
    李嘉欣
    South China Journal of Cardiology, 2017, 18 (04) : 307 - 311
  • [49] Framingham Risk Score inadequately predicts patients at risk of a first ST elevation myocardial infarction
    Mukete, Bertram
    Xiang, Yufei
    Moran, Lynn
    Matsumura, Martin E.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A348 - A348
  • [50] Risk factors for in-hospital mortality in patients with acute myocardial infarction in China
    刘倩倩
    China Medical Abstracts(Internal Medicine), 2020, 37 (02) : 83 - 83